KR930702509A - 사람 면역결핍 바이러스(hiv)면역치료제 - Google Patents
사람 면역결핍 바이러스(hiv)면역치료제Info
- Publication number
- KR930702509A KR930702509A KR1019930701196A KR930701196A KR930702509A KR 930702509 A KR930702509 A KR 930702509A KR 1019930701196 A KR1019930701196 A KR 1019930701196A KR 930701196 A KR930701196 A KR 930701196A KR 930702509 A KR930702509 A KR 930702509A
- Authority
- KR
- South Korea
- Prior art keywords
- hiv
- protein
- capacity
- immunotherapy
- infected
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title 2
- 238000009169 immunotherapy Methods 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 2
- 102100034343 Integrase Human genes 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000017960 syncytium formation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74856291A | 1991-08-22 | 1991-08-22 | |
| US7/748,562 | 1991-08-22 | ||
| PCT/US1992/007111 WO1993004090A1 (en) | 1991-08-22 | 1992-08-24 | Hiv immunotherapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR930702509A true KR930702509A (ko) | 1993-09-09 |
| KR100251823B1 KR100251823B1 (ko) | 2000-04-15 |
Family
ID=25009973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930701196A KR100251823B1 (ko) | 1991-08-22 | 1992-08-24 | 사람 면역 결핍 바이러스(hiv) 감염의 면역치료용 모노클로날 항체 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0554446B1 (ko) |
| JP (1) | JP2888980B2 (ko) |
| KR (1) | KR100251823B1 (ko) |
| AT (1) | ATE173024T1 (ko) |
| AU (1) | AU659677B2 (ko) |
| CA (1) | CA2094611C (ko) |
| DE (1) | DE69227500T2 (ko) |
| RU (1) | RU2128222C1 (ko) |
| WO (1) | WO1993004090A1 (ko) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995006119A1 (en) * | 1993-08-24 | 1995-03-02 | Scotgen Limited | Recombinant humanized anti-human immunodeficiency virus antibody |
| JP2888981B2 (ja) * | 1992-08-24 | 1999-05-10 | 日清食品株式会社 | Ｈｉｖ免疫療法 |
| AU681633B2 (en) * | 1993-03-11 | 1997-09-04 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Anti-HIV monoclonal antibody |
| US5618922A (en) * | 1994-07-25 | 1997-04-08 | Nissin Shokuhin Kabushiki Kaisha | NM03 antibody materials and methods |
| US7048935B2 (en) | 1995-04-27 | 2006-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| US6428790B1 (en) | 1995-04-27 | 2002-08-06 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use |
| US5843882A (en) | 1995-04-27 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides |
| US6193982B1 (en) | 1995-04-27 | 2001-02-27 | The United States Of America As Represented By The Department Of Health & Human Services | Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120 |
| US6780847B2 (en) | 1995-04-27 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
| US6987096B1 (en) | 1995-04-27 | 2006-01-17 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof |
| JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
| DE69938062T2 (de) | 1998-12-31 | 2009-01-15 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Modifizierte hiv env polypeptide |
| CN1339319A (zh) * | 2000-08-18 | 2002-03-13 | 清华大学 | 一种治疗艾滋病的药物及其制备方法 |
| EP1456382B1 (en) | 2001-03-22 | 2007-08-08 | The United States of America, represented by the Secretary, Department of Health and Human Services | Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0295803B1 (en) * | 1987-05-29 | 1993-11-03 | Shuzo Matsushita | Monoclonal antibodies |
| DE3853779T2 (de) * | 1987-05-29 | 1995-09-07 | Baylor College Medicine | Hiv-1 neutralisierende monoklonale antikörper. |
| EP0339504A3 (en) * | 1988-04-26 | 1990-09-12 | The Du Pont Merck Pharmaceutical Company | Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals |
| IL94624A0 (en) * | 1989-06-05 | 1991-04-15 | Repligen Corp | Human monoclonal antibodies to hiv-1 mn qq120 |
| JP2989862B2 (ja) * | 1990-07-02 | 1999-12-13 | 財団法人化学及血清療法研究所 | モノクローナル抗体 |
-
1992
- 1992-08-24 RU RU93005284A patent/RU2128222C1/ru active
- 1992-08-24 CA CA002094611A patent/CA2094611C/en not_active Expired - Fee Related
- 1992-08-24 JP JP5504629A patent/JP2888980B2/ja not_active Expired - Fee Related
- 1992-08-24 WO PCT/US1992/007111 patent/WO1993004090A1/en active IP Right Grant
- 1992-08-24 AU AU25683/92A patent/AU659677B2/en not_active Ceased
- 1992-08-24 EP EP92919658A patent/EP0554446B1/en not_active Expired - Lifetime
- 1992-08-24 KR KR1019930701196A patent/KR100251823B1/ko not_active IP Right Cessation
- 1992-08-24 AT AT92919658T patent/ATE173024T1/de not_active IP Right Cessation
- 1992-08-24 DE DE69227500T patent/DE69227500T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2888980B2 (ja) | 1999-05-10 |
| AU2568392A (en) | 1993-03-16 |
| KR100251823B1 (ko) | 2000-04-15 |
| CA2094611C (en) | 2000-07-25 |
| EP0554446A4 (ko) | 1994-02-09 |
| DE69227500D1 (de) | 1998-12-10 |
| WO1993004090A1 (en) | 1993-03-04 |
| EP0554446A1 (en) | 1993-08-11 |
| JPH06503970A (ja) | 1994-05-12 |
| CA2094611A1 (en) | 1993-02-23 |
| DE69227500T2 (de) | 1999-04-15 |
| ATE173024T1 (de) | 1998-11-15 |
| AU659677B2 (en) | 1995-05-25 |
| RU2128222C1 (ru) | 1999-03-27 |
| EP0554446B1 (en) | 1998-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR930702509A (ko) | 사람 면역결핍 바이러스(hiv)면역치료제 | |
| JPH06502539A (ja) | Ｈｉｖ−１ ｇｐ１２０のｖ３ループおよびｃｄ−４結合部位に特異的な中和ヒトモノクローナル抗体 | |
| AT398080B (de) | Immortalisierte zellinie, verfahren zu ihrer herstellung und verfahren zur herstellung von monoklonalen antikörpern sowie diagnoseverfahren und -mittel | |
| ATE238420T1 (de) | Rekombinanter humanisierter antikörper gegen menschlichen immunschwächevirus | |
| US5854400A (en) | Monoclonal antibodies which neutralize HIV-1 infection | |
| RU93005284A (ru) | Моноклональные антитела линии клеток, фармацевтические композиции, способы лечения, фрагмент антитела | |
| WO1990010457A1 (en) | Method of treating hiv infections using immunotoxins | |
| US6132721A (en) | Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same | |
| US6241986B1 (en) | Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV | |
| US5445960A (en) | Monoclonal antibodies specific for HIV and hybridomas for their production | |
| JPH05503851A (ja) | 中和および／またはａｄｃｃ仲介モノクローナルｈｉｖ抗体 | |
| KR0149848B1 (ko) | Hiv에 특이한 모노클로날 항체 및 그 제조용 하이브리도마 | |
| AU8010791A (en) | Hiv monoclonal antibody | |
| US5820865A (en) | Method to induce cytotoxic T Lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides | |
| US6200575B1 (en) | Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them | |
| ATE201698T1 (de) | Immuntherapeutika gegen hiv | |
| AU651794B2 (en) | Human monoclonal antibodies to human immunodeficiency virus | |
| RU94024562A (ru) | Антитело, полинуклеотид, клетка, способ получения антитела | |
| CN1172717C (zh) | 一种治疗艾滋病的药物及其制备方法 | |
| Benjouad et al. | Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type‐1 envelope glycoprotein | |
| AU4832097A (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
| EP0491888A4 (en) | Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection | |
| CN1238499C (zh) | 艾滋病病毒0型株的一种抗体及其生产细胞系与应用 | |
| KR100871455B1 (ko) | Ｈｉｖ 바이러스에 대한 천연 항체 | |
| WO2002026253A1 (fr) | Vaccin contre le sida, son procede de preparation et ses applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| LAPS | Lapse due to unpaid annual fee |